MX2020005915A - Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido. - Google Patents

Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.

Info

Publication number
MX2020005915A
MX2020005915A MX2020005915A MX2020005915A MX2020005915A MX 2020005915 A MX2020005915 A MX 2020005915A MX 2020005915 A MX2020005915 A MX 2020005915A MX 2020005915 A MX2020005915 A MX 2020005915A MX 2020005915 A MX2020005915 A MX 2020005915A
Authority
MX
Mexico
Prior art keywords
compositions
aqueous solution
injectable aqueous
human glucagon
copolyamino acid
Prior art date
Application number
MX2020005915A
Other languages
English (en)
Inventor
Alexandre Geissler
Richard Charvet
You-Ping Chan
Romain Noel
Nicolas Laurent
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1761809A external-priority patent/FR3074683B1/fr
Application filed by Adocia filed Critical Adocia
Publication of MX2020005915A publication Critical patent/MX2020005915A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención también se refiere a composiciones físicamente estables en forma de una solución acuosa inyectable, para las cuales el pH está comprendido de 6.0 o 8.0, que comprenden al menos: a) glucagón humano, y b) un copolaminoácido con cargas de carboxilato y radicales hidrofóbicos, En una modalidad, las composiciones de acuerdo con la invención también comprenden una hormona gastrointestinal.
MX2020005915A 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido. MX2020005915A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762606137P 2017-12-07 2017-12-07
FR1761809A FR3074683B1 (fr) 2017-12-07 2017-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR1855939 2018-06-29
PCT/EP2018/084065 WO2019110837A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Publications (1)

Publication Number Publication Date
MX2020005915A true MX2020005915A (es) 2020-10-19

Family

ID=66750442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005915A MX2020005915A (es) 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.

Country Status (7)

Country Link
US (1) US20210386830A1 (es)
IL (1) IL275184A (es)
MA (1) MA51018A (es)
MX (1) MX2020005915A (es)
PH (1) PH12020550828A1 (es)
SA (1) SA520412140B1 (es)
WO (1) WO2019110837A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
EP4091625A1 (en) 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
US20110097386A1 (en) 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
WO2011138802A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
EP2635296B1 (en) 2010-11-03 2014-12-24 Arecor Limited Novel composition comprising glucagon
WO2013101749A1 (en) 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
CN107583039A (zh) * 2012-01-09 2018-01-16 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US9334316B2 (en) 2014-04-11 2016-05-10 Oregon Health & Science University Formulations comprising glucagon
CN109562064A (zh) * 2016-06-07 2019-04-02 阿道恰公司 包含人胰高血糖素和统计共聚氨基酸的可注射水溶液形式的组合物

Also Published As

Publication number Publication date
SA520412140B1 (ar) 2023-02-26
US20210386830A1 (en) 2021-12-16
MA51018A (fr) 2020-10-14
WO2019110837A1 (fr) 2019-06-13
PH12020550828A1 (en) 2021-05-10
IL275184A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2018015070A (es) Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
PH12018502558A1 (en) Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
MA53356A (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
PH12018502714A1 (en) Nicotine particles and compositions
MX2016005395A (es) Formulacion estable de insulina glulisina.
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
MX2019005855A (es) Formulaciones que se pueden pulverizar.
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
SG11202005322RA (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
SG11202005320VA (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MY193928A (en) Aqueous primer
MX2020006670A (es) Composicion acuosa que comprende acido 2-(dimetil-1h-pirazol-1-il) succinico y amoniaco.
EA202091387A1 (ru) Композиции в форме инъецируемого водного раствора, содержащие человеческий глюкагон и сополиаминокислоту
SG11201804902UA (en) A composition for improving memory, learning ability, and cognitive ability
MY187571A (en) Krill oil preparations with optimal mineral and metal composition, low impurities and low and stable tma levels
PH12019501946A1 (en) Liquid composition containing pradofloxacin
FR3074683B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
EP3426043A4 (en) PLANT-BASED FORMULATION FOR INCREASING THE PH OF THE HUMAN BODY AND MOVING IT FROM AC PH PHASE TO ALKALINE PH